PREScribing INFORMATION

Pr Atropine Sulfate Injection USP

0.1 mg/mL

Sterile Solution

Anticholinergic

Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, QC
H9H 2M5

DATE OF REVISION:
January 19, 2018

Control No. 212184
**ACTION AND CLINICAL PHARMACOLOGY**

Atropine Sulfate Injection USP is commonly classified as an anticholinergic or antiparasymathetic (parasympatholytic) drug. More precisely, however, it is termed an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters.

Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters.

Atropine-induced parasympathetic inhibition may be preceded by a transient phase of stimulation, especially on the heart, where small doses first slow the rate before characteristic tachycardia develops due to paralysis of vagal control. Atropine exerts a more potent and prolonged effect on heart, intestine and bronchial muscle than scopolamine, but its action on the iris, ciliary body and certain secretory glands is weaker than that of scopolamine. Unlike the latter, atropine, in clinical doses, does not depress the central nervous system but may stimulate the medulla and higher cerebral centers. Although mild vagal excitation occurs, the increased respiratory rate and (sometimes) increased depth of respiration produced by atropine are more probably the result of bronchiolar dilatation. Accordingly, atropine is an unreliable respiratory stimulant and large or repeated doses may depress respiration.

Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasymathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine also may lessen the degree of partial heart block when vagal activity is an etiologic factor. In some patients with complete heart block, the idioventricular rate may be accelerated by atropine; in others, the rate is stabilized. Occasionally, a large dose may cause atrioventricular (A-V) block and nodal rhythm.

Atropine, in clinical doses, counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, atropine does not exert a striking or uniform effect on blood vessels or blood pressure. Systemic doses slightly raise systolic and lower diastolic pressures and can produce significant postural hypotension. Such doses also slightly increase cardiac output and decrease central venous pressure. Occasionally, therapeutic doses dilate cutaneous blood vessels, particularly in the “blush” area (atropine flush), and may cause atropine “fever” due to suppression of sweat gland activity in infants and small children.
Atropine disappears rapidly from the blood following injection and is distributed throughout the body. Much of the drug is destroyed by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including milk. Atropine readily crosses the placental barrier and enters the fetal circulation.

Sodium chloride added to render the solution isotonic for injection of the active ingredient is present in amounts insufficient to affect serum electrolyte balance of sodium (Na⁺) and chloride (Cl⁻) ions.

**INDICATIONS AND CLINICAL USES**

Atropine Sulfate Injection USP is indicated:

1. as an antisialogogue for pre-anesthetic medication to prevent or reduce secretions of the respiratory tract;
2. to restore cardiac rate and arterial pressure during anesthesia when vagal stimulation, produced by intra-abdominal surgical traction, causes a sudden decrease in pulse rate and cardiac action;
3. to lessen the degree of atrioventricular (A-V) heart block when increased vagal tone is a major factor in the conduction defect, as in some cases due to digitalis;
4. to overcome severe bradycardia and syncope due to a hyperactive carotid sinus reflex;
5. as an antidote (with external cardiac massage) for cardiovascular collapse from the injudicious use of a choline ester (cholinergic) drug;
6. in the treatment of anticholinesterase poisoning from organophosphorus insecticides; and
7. as an antidote for the “rapid” type of mushroom poisoning due to the presence of the alkaloid, muscarine, in certain species of fungus such as *Amanita muscaria*.

**CONTRAINDICATIONS**

Atropine Sulfate Injection USP generally is contraindicated in patients with glaucoma, pyloric stenosis or prostatic hypertrophy, except in doses ordinarily used for pre-anesthetic medication.

**WARNINGS**

Atropine Sulfate Injection USP is a highly potent drug and due care is essential to avoid overdosage especially with intravenous administration. Children are more susceptible than adults to the toxic effects of anticholinergic agents.

**PRECAUTIONS**

Atropine Sulfate Injection USP should be used with caution in all individuals over 40 years of age. Conventional systemic doses may precipitate acute glaucoma in susceptible patients, convert partial
organic pyloric stenosis into complete obstruction, and lead to complete urinary retention in patients with prostatic hypertrophy or cause inspissation of bronchial secretions and formation of dangerous viscid plugs in patients with chronic lung disease.

**Pregnancy**
Animal reproduction studies have not been conducted with atropine. It also is not known whether atropine can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. Atropine should be given to a pregnant woman only if clearly needed.

**ADVERSE REACTIONS**

Most of the side effects of atropine are directly related to its antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur with chronic administration of therapeutic doses. Anhidrosis also may occur and produce heat intolerance or impair temperature regulation in persons living in a hot environment. Constipation and difficulty in micturition may occur in elderly patients. Occasional hypersensitivity reactions have been observed, especially skin rashes, which in some instances progressed to exfoliation.

Adverse effects following single or repeated injections of atropine are most often the result of excessive dosage. These include palpitation, dilated pupils, difficulty in swallowing, hot dry skin, thirst, dizziness, restlessness, tremor, fatigue and ataxia. Toxic doses lead to marked palpitation, restlessness and excitement, hallucinations, delirium and coma. Depression and circulatory collapse occur only with severe intoxication. In such cases, blood pressure declines and death due to respiratory failure may ensue, following paralysis and coma.

**SYMPTOMS AND TREATMENT OF OVERDOSAGE**

In the event of toxic overdosage (see **ADVERSE REACTIONS**), a short-acting barbiturate or diazepam may be given, as needed, to control marked excitement and convulsions. Large doses for sedation should be avoided because central depressant action may coincide with the depression occurring late in atropine poisoning. Central stimulants are not recommended. Physostigmine, given as an atropine antidote by slow intravenous injection of 1 to 4 mg (0.5 to 1.0 mg in children), rapidly abolishes delirium and coma caused by large doses of atropine. Since physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and repeated doses may be required. Artificial respiration with oxygen may be necessary. Ice bags and alcohol sponges help to reduce fever, especially in children.

The fatal adult dose of atropine is not known; 200 mg doses have been used and doses as high as 1000 mg have been given.

In children, 10 mg or less may be fatal. With a dose as low as 0.5 mg, undesirable minimal symptoms or responses of overdosage may occur. These increase in severity and extent with larger doses of the drug (excitement, hallucinations, delirium and coma with a dose of 10 mg or more).
DOSAGE AND ADMINISTRATION

Atropine Sulfate Injection USP may be administered subcutaneously, intramuscularly or intravenously. The average adult dose is 0.5 mg (5 mL of a 0.1 mg/mL solution), range 0.4 to 0.6 mg (4 to 6 mL). As an antispasmodic, it is usually injected intramuscularly prior to induction of anesthesia. This produces only minimal blocking of vagal activity. In children, the dosage ranges from 0.1 mg in the newborn to 0.6 mg in a child aged 12 years, injected subcutaneously 30 minutes before surgery. During surgery, the drug is given intravenously when reduction in pulse rate and cessation of cardiac action are due to increased vagal activity; however, if the anesthetic is cyclopropane, doses less than 0.4 mg should be used and should be given slowly to avoid the possible production of ventricular arrhythmia. Usual doses are used to reduce severe bradycardia and syncope associated with hyperactive carotid sinus reflex. For bradyarrhythmias, the usual intravenous adult dosage ranges from 0.4 to 1 mg (4 to 10 mL of a 0.1 mg/mL solution) every one to two hours as needed; larger doses up to a maximum of 2 mg may be required. In children, intravenous dosage ranges from 0.01 to 0.03 mg per kg of body weight. Atropine is also a specific antidote for cardiovascular collapse resulting from injudicious administration of choline ester. When cardiac arrest has occurred, external cardiac massage or other method of resuscitation is required to distribute the drug after intravenous injection.

In anticholinesterase poisoning from exposure to insecticides, large doses of at least 2 to 3 mg (20 to 30 mL of a 0.1 mg/mL solution) should be administered parenterally and repeated until signs of atropine intoxication appear. In the “rapid” type of mushroom poisoning, atropine should be given in doses sufficient to control parasympathomimetic signs before coma and cardiovascular collapse supervene.

DESCRIPTION

Atropine Sulfate Injection USP is a sterile, nonpyrogenic solution of atropine sulfate monohydrate in water for injection with sodium chloride sufficient to render the solution isotonic. It is administered parenterally by subcutaneous, intramuscular or intravenous injection.

Each milliliter (mL) contains atropine sulfate, monohydrate 0.1 mg and sodium chloride 9 mg (for tonicity) in water for injection, pH 4.2 (3.0 to 6.5) adjusted with sulfuric acid and/or sodium hydroxide.

The solution contains no bacteriostat, antimicrobial agent nor added buffer (except for pH adjustment) and is intended for use only as a single-dose injection. When smaller doses are required, the unused portion should be discarded.

STABILITY AND STORAGE RECOMMENDATIONS

Store between 20°C and 25°C. Protect from freezing and excessive heat.
AVAILABILITY OF DOSAGE FORMS

Atropine Sulfate Injection USP is supplied in single-dose containers as follows:

<table>
<thead>
<tr>
<th>Container</th>
<th>Size</th>
<th>Concentration</th>
<th>Total Content (Atropine)</th>
<th>Needle</th>
</tr>
</thead>
<tbody>
<tr>
<td>LifeShield® Abboject®</td>
<td>5 mL</td>
<td>0.1 mg/mL</td>
<td>0.5 mg</td>
<td>20-gauge</td>
</tr>
<tr>
<td>Syringe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LifeShield® Abboject®</td>
<td>10 mL</td>
<td>0.1 mg/mL</td>
<td>1.0 mg</td>
<td>20-gauge</td>
</tr>
<tr>
<td>Syringe</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Medication, fluid path and needle are sterile and nonpyrogenic if caps and needle cover are undisturbed and the package is intact.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Do not use unless the solution is clear and container or seal intact. Discard if it contains a precipitate.

Single-dose; discard unused portion.

Last revised: January 19, 2018